ARS Pharmaceuticals Enters Material Definitive Agreement
Ticker: SPRY · Form: 8-K · Filed: Sep 23, 2024 · CIK: 1671858
| Field | Detail |
|---|---|
| Company | Ars Pharmaceuticals, Inc. (SPRY) |
| Form Type | 8-K |
| Filed Date | Sep 23, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-definitive-agreement, corporate-action
TL;DR
ARS Pharma signed a big deal, details TBD.
AI Summary
On September 17, 2024, ARS Pharmaceuticals, Inc. entered into a Material Definitive Agreement. The filing does not disclose specific details of the agreement, such as the counterparty or financial terms, but indicates it is a significant event for the company.
Why It Matters
This filing signals a significant development for ARS Pharmaceuticals, potentially impacting its future operations, partnerships, or financial standing.
Risk Assessment
Risk Level: medium — The lack of specific details in the filing creates uncertainty about the nature and implications of the agreement.
Key Players & Entities
- ARS Pharmaceuticals, Inc. (company) — Registrant
- Silverback Therapeutics, Inc. (company) — Former company name
FAQ
What is the nature of the Material Definitive Agreement entered into by ARS Pharmaceuticals?
The filing states that ARS Pharmaceuticals, Inc. entered into a Material Definitive Agreement on September 17, 2024, but does not provide specific details about the agreement's terms or counterparty.
Who is the counterparty to this Material Definitive Agreement?
The filing does not disclose the name of the other party involved in the Material Definitive Agreement.
What is the effective date of this Material Definitive Agreement?
The earliest event reported, which is the entry into the Material Definitive Agreement, is dated September 17, 2024.
Has ARS Pharmaceuticals changed its name recently?
The filing indicates that the former company name was Silverback Therapeutics, Inc., with a date of name change on April 12, 2016.
Where is ARS Pharmaceuticals headquartered?
ARS Pharmaceuticals, Inc. is headquartered at 11682 El Camino Real, Suite 120, San Diego, California, 92130.
Filing Stats: 1,041 words · 4 min read · ~3 pages · Grade level 14.9 · Accepted 2024-09-23 16:15:31
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share SPRY The Nasdaq
Filing Documents
- d834306d8k.htm (8-K) — 28KB
- 0001193125-24-223676.txt ( ) — 152KB
- spry-20240917.xsd (EX-101.SCH) — 3KB
- spry-20240917_lab.xml (EX-101.LAB) — 18KB
- spry-20240917_pre.xml (EX-101.PRE) — 11KB
- d834306d8k_htm.xml (XML) — 4KB
Forward-Looking Statements
Forward-Looking Statements This report contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon the Company's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation: the ability to maintain regulatory approval for neffy ; results from clinical trials may not be indicative of results that may be observed in the future; potential safety and other complications from neffy ; neffy may fail to achieve the degree of market acceptance by allergists, pediatricians and other physicians, patients, caregivers, third-party payors and others in the medical community necessary for commercial success; if the Company is unable to fully develop sales, marketing and distribution capabilities, it may not be successful in commercializing neffy ; the labeling for neffy in any future indication or patient population; the scope, progress and expansion of developing and commercializing neffy ; the potential for payors to delay, limit or deny coverage for neffy ; the size and growth of the market therefor and the rate and degree of market acceptance thereof vis--vis intramuscular injectable products; the scope, progress and expansion of developing and commercializing neffy , including the ability to enter into distribution and/or partnering arrangements and obtain favorable reimbursement; the Company's ability to protect its intellectual property position; and the impact of government laws, prescription drug price controls and regulations. Additional risks and uncertai
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ARS PHARMACEUTICALS, INC. Date: September 23, 2024 By: /s/ Richard Lowenthal Richard Lowenthal, M.S., MBA President and Chief Executive Officer